Join BIOCYTOGEN at Bio EU Spring 2025

Join BIOCYTOGEN at Bio EU Spring 2025

We’re pleased to share that we will be exhibiting at BIO-Europe Spring 2025! Scheduled from March 17th to 19th in Milan, Italy, this prestigious event offers a key stage for biotechnology companies to present their cutting-edge advancements. Providing unmatched opportunities for networking, BIO-Europe Spring brings together innovators, investors, and biopharmaceutical leaders to foster collaboration and propel progress in the life sciences industry.

What is Bio EU Spring 2025?

BIO-Europe Spring 2025 is a leading partnering conference in the life sciences industry, taking place in Milan, Italy. This event combines Milan’s rich cultural heritage with the dynamic innovation of the life sciences sector, providing an exceptional platform for fostering global partnerships.

The conference gathers a diverse array of participants, including senior executives from top biotech firms, business development teams from large and midsize pharmaceutical companies, investors, and industry experts. By propelling the next wave of innovators onto the global stage, BIO-Europe Spring serves as a critical hub for networking, deal-making, and advancing the future of life sciences.

Event Overview  

Date: March 17th – 19th 

Venue: Allianz MiCo. Piazzale Carlo Magno, 1/Gate 16, 20149 Milano MI, Italy

Event Schedule

The Bio EU Spring 2025 in Milan, Italy will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the Bio EU Spring 2025 agenda.

About BIOCYTOGEN

Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).

We look forward to seeing you at the Bio EU Spring 2025 in Milan, Italy!

Share:

Back to top
WordPress Double Opt-in by Forge12